EGFR and non-small cell lung carcinoma: Both studies of the authors Oh et al. [225,226] confirmed that these compounds directly interacted with EGFR and Met in gefitinib-sensitive (HCC827) and gefitinib-resistant (HCC827GR) NSCLC cell line models, and also suppressed their kinase activity at a concentration of 5 μmol/L.